trending Market Intelligence /marketintelligence/en/news-insights/trending/4HZsHP6N0IzVZSczZu0ylg2 content esgSubNav
In This List

India's Zydus Healthcare acquires six drug brands from Merck

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


India's Zydus Healthcare acquires six drug brands from Merck

India's Zydus Healthcare Ltd. acquired six brands from Merck & Co. Inc. that fall under the categories of men's health, women's health, wound management and cardiovascular therapy.

The brands are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten, which had sales of 840 million Indian rupees in 2015.

The companies did not disclose the financial terms of the acquisition.

As of Dec. 28, US$1 was equivalent to 68.21 Indian rupees.